Investigation of Parvovirus B19 IgM and IgG Positivity Rates in Pediatric Hematology Patients

Basit Öğe Kaydı
dc.contributor.authorGorkem, Aysun
dc.contributor.authorUgur, Ayse Ruveyda
dc.contributor.authorOzdemir, Mehmet
dc.contributor.authorFeyzioglu, Bahadir
dc.contributor.authorBaykan, Mahmut
dc.date.accessioned2024-02-23T14:16:52Z
dc.date.available2024-02-23T14:16:52Z
dc.date.issued2018
dc.departmentNEÜen_US
dc.description.abstractHuman parvovirus B19 is a frequent etiologic agent causing erythema infectiosum in children. It has recently been suggested that parvovirus B19 may be latent after infection and cause reactive infections especially in immunosuppressed patients with hematological problems. In this study, we aimed to investigate the parvovirus B19 immunoglobulin M (IgM) and immunoglobulin G (IgG) seropositivity rates of patients evaluated in a pediatric hematology clinic. We retrospectively screened the laboratory results of parvovirus B19 IgM and IgG antibody assays of children less than 18 years, who consulted pediatric in-and-outpatient clinics between 2013 and 2016. Parvovirus B19 IgM and IgG antibodies were investigated in serum samples by using enzymelinked immunosorbent assay method in the Medical Microbiology Laboratory. Parvovirus B19 IgM antibodies were detected in 109 of 602 patients attending pediatric hematology clinics (18.1%). Parvovirus B19 IgG antibody was detected in 244 of 952 patients attending pediatric hematology clinics (25.6%). Parvovirus B19 IgM and IgG positivity in samples from pediatric in-and-outpatient clinics other than pediatric hematology were 2.8% and 35.7%, respectively. Parvovirus IgM and IgG positivity in serum samples sent from the pediatric hematology clinic and outpatients was statistically significant compared with those sent from pediatric clinics other than pediatric hematology (p = 0.0001 and p = 0.0008, respectively). The higher detection rate of serum parvovirus B19 IgM positivity in patients under the follow-up of pediatric hematology clinics suggests that immune suppression-related viral reinfection or persistence may occur in these patients.en_US
dc.identifier.doi10.1055/s-0038-1631877
dc.identifier.endpage276en_US
dc.identifier.issn1305-7707
dc.identifier.issn1305-7693
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85042183298en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage274en_US
dc.identifier.urihttps://doi.org/10.1055/s-0038-1631877
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12840
dc.identifier.volume13en_US
dc.identifier.wosWOS:000449161500003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofJournal Of Pediatric Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectParvovirus B19en_US
dc.subjectIgmen_US
dc.subjectIggen_US
dc.subjectPediatric Patienten_US
dc.titleInvestigation of Parvovirus B19 IgM and IgG Positivity Rates in Pediatric Hematology Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu